Menu
Search
|

Menu

Close
X

Compugen Ltd CGEN.OQ (NASDAQ Stock Exchange Global Market)

3.08 USD
-0.03 (-0.81%)
As of 11:15 PM IST
chart
Previous Close 3.10
Open 3.05
Volume 21,187
3m Avg Volume 40,592
Today’s High 3.15
Today’s Low 3.05
52 Week High 5.40
52 Week Low 2.25
Shares Outstanding (mil) 51.13
Market Capitalization (mil) 175.64
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.50 Mean rating from 2 analysts

KEY STATS

Revenue (mm, USD)
FY17
0
FY16
1
FY15
9
EPS (USD)
FY17
-0.350
FY16
-0.620
FY15
-0.400
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
1,427.98
5.77
Price to Book (MRQ)
vs sector
3.84
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
0.00
16.52
LT Debt to Equity (MRQ)
vs sector
0.00
12.22
Return on Investment (TTM)
vs sector
-52.36
14.43
Return on Equity (TTM)
vs sector
-54.94
16.13

EXECUTIVE LEADERSHIP

Paul Sekhri
Chairman of the Board, Since 2017
Salary: --
Bonus: --
Anat Cohen-Dayag
President, Chief Executive Officer, Director, Since 2014
Salary: --
Bonus: --
Ari Krashin
Chief Financial Officer, Since 2014
Salary: --
Bonus: --
Zurit Levine
Vice President - Research and Discovery, Since 2011
Salary: --
Bonus: --
John Hunter
Vice President - Antibody Research & Development, Since 2012
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

Azrieli Center, 26 Harokmim St.
HOLON     5885849

Phone: +9723.7658585
Site: cgen.com/

Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.

SPONSORED STORIES